Goodwin Procter LLP advised SpringWorks Therapeutics on the deal. SpringWorks Therapeutics (Nasdaq: SWTX) announced its underwritten public offering of 5,637,254 shares of its common stock at…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
